Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.

Abstract : In the ANRS EASIER trial where treatment-experienced patients switched from enfuvirtide (ENF) to raltegravir (RAL), a high incidence of transaminase elevation was reported in the RAL arm. We compared the incidence of emergent liver enzyme elevations (LEE) of grade 2 or more among patients randomized to the maintenance ENF arm or the switch RAL arm up to W24. We also assessed the overall incidence of LEE over the 48-week duration of the trial and baseline risk factors for grade 2 or more alanine aminotransferase (ALT) elevation using univariate and multivariate analyses. During the first 24 weeks, 6/84 (7.1 %) and 2/85 patients (2.4 %) presented with ALT elevation of grade 2 or more in the RAL and ENF arms, respectively (p = 0.21). Grade 2 or more γGT and ALP elevations were seen in 18 and 11 % (p = 0.35), and 5 and 1 % (p = 0.14) of patients in the RAL and ENF arms, respectively. The 48-week incidence of grade 2 or more LEE was 11.6 per 100-pts-years for ALT, 24.5 per 100-pts-years for γ-GT and 4.5 per 100-pts-years for ALP, respectively. In the multivariate analysis, tipranavir/ritonavir use (OR 3.66; 95 % CI [1.20-11.1], p = 0.022) and elevated ALT at baseline (OR 10.3; 95 % CI [2.67-39.6], p < 10(-3)) were significantly associated with a grade 2 or more ALT elevation during follow-up. The incidence of LEE was relatively high in these highly treatment-experienced patients switching to a RAL-based regimen. Both tipranavir/ritonavir use and high baseline ALT levels were associated with an increased risk of ALT. ClinicalTrials.gov identifier: NCT00454337.
Type de document :
Article dans une revue
AIDS Research and Therapy, BioMed Central, 2016, 13 (1), pp.17. 〈10.1186/s12981-016-0101-3〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01322538
Contributeur : Bmc Bmc <>
Soumis le : vendredi 27 mai 2016 - 11:42:03
Dernière modification le : jeudi 5 avril 2018 - 10:36:55
Document(s) archivé(s) le : dimanche 28 août 2016 - 10:37:39

Fichier

12981_2016_Article_101.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Citation

Nathalie De Castro, Joséphine Braun, Isabelle Charreau, Alain Lafeuillade, Jean-Paul Viard, et al.. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.. AIDS Research and Therapy, BioMed Central, 2016, 13 (1), pp.17. 〈10.1186/s12981-016-0101-3〉. 〈inserm-01322538〉

Partager

Métriques

Consultations de la notice

88

Téléchargements de fichiers

47